Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1990-6-8
|
pubmed:abstractText |
Sixty postmenopausal women with advanced breast cancer entered a phase II study, evaluating idarubicin (IDA) in a weekly schedule. Starting dose was 22.5 mg/m2, and median age was 65 years. Five patients were considered ineligible and the response rate among 55 eligible patients was 33%. Median time to treatment failure was 19 weeks and median duration of tumor regression for 18 responding patients was 40 weeks. Hematologic toxicity was moderate and non-hematologic toxicity was mild. The study shows that IDA, administered orally in a weekly schedule, has pharmacodynamic properties comparable to IDA in a 3-weekly schedule and to doxorubicin in the treatment of advanced breast cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0284-186X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
143-6
|
pubmed:dateRevised |
2009-5-12
|
pubmed:meshHeading |
pubmed-meshheading:2334567-Administration, Oral,
pubmed-meshheading:2334567-Adult,
pubmed-meshheading:2334567-Aged,
pubmed-meshheading:2334567-Breast Neoplasms,
pubmed-meshheading:2334567-Drug Administration Schedule,
pubmed-meshheading:2334567-Drug Evaluation,
pubmed-meshheading:2334567-Female,
pubmed-meshheading:2334567-Humans,
pubmed-meshheading:2334567-Idarubicin,
pubmed-meshheading:2334567-Menopause,
pubmed-meshheading:2334567-Middle Aged
|
pubmed:year |
1990
|
pubmed:articleTitle |
Weekly oral idarubicin in postmenopausal women with advanced breast cancer. A phase II study.
|
pubmed:affiliation |
Department of Oncology ONA, Finsen Institute, Copenhagen, Denmark.
|
pubmed:publicationType |
Journal Article
|